Adamis Pharmaceuticals Corp (NASDAQ:ADMP) price target set to $10.00 by Maxim Group

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) price target set to $10.00 by Maxim Group

Dec 07, 2018 (Market Exclusive via COMTEX) —

Analyst Ratings For Adamis Pharmaceuticals Corp (NASDAQ:ADMP)

Today, Maxim Group set its price target on Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to $10.00 per share.

There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Adamis Pharmaceuticals Corp (NASDAQ:ADMP) is Buy with a consensus target price of $6.6250 per share, a potential 137.46% upside.

Some recent analyst ratings include

11/12/2018-Adamis Pharmaceuticals Corp (NASDAQ:ADMP) gets downgraded to Neutral by B. Riley with a price target of $2.50 On 6/2/2016 David J Marguglio, VP, sold 700 with an average share price of $9.00 per share and the total transaction amounting to $6,300.00. On 5/16/2016 David J Marguglio, SVP, sold 4,000 with an average share price of $8.08 per share and the total transaction amounting to $32,320.00. On 5/9/2016 David J Marguglio, SVP, sold 4,860 with an average share price of $10.00 per share and the total transaction amounting to $48,600.00. On 5/4/2016 David J Marguglio, SVP, sold 4,860 with an average share price of $9.17 per share and the total transaction amounting to $44,566.20. On 5/3/2016 David J Marguglio, SVP, sold 1,140 with an average share price of $9.00 per share and the total transaction amounting to $10,260.00. On 4/14/2016 David J Marguglio, SVP, sold 12,000 with an average share price of $7.52 per share and the total transaction amounting to $90,240.00. On 8/14/2015 Robert B Rothermel, Director, bought 7,000 with an average share price of $3.33 per share and the total transaction amounting to $23,310.00.

About Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory

Read More Here...

Bookmark the permalink.